Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

NCT02077881 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

157

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Adenocarcinoma
Metastatic Pancreatic Cancer

Interventions

DRUG: Nab-Paclitaxel
DRUG: Gemcitabine
DRUG: Indoximod

Sponsor

NewLink Genetics Corporation